Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Soligenix, Inc. (SNGX) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Soligenix is a development-stage biopharmaceutical company engaged in developing products for the treatment of serious inflammatory diseases with unmet medical need. The company is developing several biodefense vaccines and therapeutics as well as proprietary formulations of oral BDP for the prevention and treatment of gastrointestinal disorders characterized by severe inflammation. Soligenix is also developing its novel innate defense regulator technology, SGX942, to treat oral mucositis. For more information, visit the company’s Web site at www.soligenix.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below:

This entry was posted in BIO Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *